Psoriasis drug market will reach $8.9bn in 2018

Monday 4 November 2013, Amsterdam

This new report predicts the world psoriasis drug market will be worth $8.9bn in 2018. Those products, treating that indication, generated $6bn in 2012, according to Psoriasis Treatment: World Drug Market 2013-2023, published in September 2013.

This study forecasts the overall market for psoriasis drugs will expand steadily from 2013 to 2023. That expansion will be due to the launch of novel, more-efficacious treatments and the rising demand for psoriasis medicines in emerging countries. This increasing demand is driven by expanding middle class populations and rising healthcare spending. In addition, links with cardiovascular mortality and diabetes mean awareness of psoriasis as a serious disease increases. Psoriasis treatment needs long term drug application, generating a high volume of sales.

Jennifer Taylor, a pharmaceutical industry analyst, said: “The strength of the psoriasis drug market stems from the introduction in 2004 of biologic drugs for that indication. These novel and expensive therapies provide a treatment option for patients with severe forms of the disease, which may not have been treated before biologic drugs became available. However, patients suffering from moderate-to-severe forms of psoriasis make up only 20% of cases. Mild cases of psoriasis represent a large patient population for which there is a lack of adequately tolerable and efficacious treatments. That need is limiting the psoriasis drug market as a whole.

“The main unmet need is for an agent that is as effective as the biologics, that is safe enough to use in the treatment of mild cases of psoriasis, and that is not an injection. Although there is a well stocked R&D pipeline, with drug candidates that go some way to meeting these demands, a drug that meets this need remains elusive, restricting the psoriasis drug market. However, the industry will achieve strong growth with the launch of novel interleukin inhibitors, which have demonstrated efficacy, as well as a novel small molecule drug, Apremilast. These compounds will become important players in the psoriasis drug market during the forecast period 2013-2023.”

This new report shows revenue forecasts to 2023 at overall world market, submarket, product and national level. It predicts revenues for the submarkets of biologics, small-molecule systemic drugs, and topical medications. The work includes revenue forecasts for the ten leading drugs treating psoriasis, as well as four pipeline compounds expected on the market: Apremilast, secukinumab, ixekizumab, and MK-3222. It also examines leading companies in 2013, assessing their market shares, activities and prospects.

In addition, that study analyses national markets – the US, Japan, Germany, France, Italy, the UK, Spain (EU5), Brazil, Russia, India and China (BRIC) – and provides revenue forecasts to 2023 for those countries. It assesses, too, the R&D pipeline and presents interviews with authorities on psoriasis.